

EDITED BY RAMON RIOS TORRES

SPIRO COMPOUNDS

SYNTHESIS AND APPLICATIONS



WILEY

Spiro Compounds

Spiro Compounds

Synthesis and Applications

Edited by

Ramon Rios Torres

*University of Southampton
Southampton, United Kingdom*

WILEY

This edition first published 2022
© 2022 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Ramon Rios Torres to be identified as the author of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Riós Torres, Ramón, author.

Title: Spiro compounds : synthesis and applications / Ramon Rios Torres,

University of Southampton, Southampton, United Kingdom.

Description: First edition. | Hoboken, NJ : Wiley, 2022. | Includes index.

Identifiers: LCCN 2021031988 (print) | LCCN 2021031989 (ebook) | ISBN

9781119567639 (hardback) | ISBN 9781119567622 (adobe pdf) | ISBN

9781119567653 (epub)

Subjects: LCSH: Organic compounds--Structure.

Classification: LCC QD255.4 .R56 2022 (print) | LCC QD255.4 (ebook) | DDC

547/.5--dc23

LC record available at <https://lcn.loc.gov/2021031988>

LC ebook record available at <https://lcn.loc.gov/2021031989>

Cover Design: Wiley

Cover Image: © Connect world/Shutterstock

Set in 9.5/12.5pt STIXTwoText by Straive, Pondicherry, India

Contents

List of Contributors *xi*

Preface *xiii*

- 1 Spiro Compounds: A Brief History** *1*
Marta Meazza
 - 1.1 Notes on IUPAC Rules for Spiro Compounds *6*
References *7*

- 2 Selected Applications of Spirocycles in Medicinal Chemistry** *9*
Matthias Baud
 - 2.1 Introduction *9*
 - 2.2 General Features *15*
 - 2.3 Property Optimization in Bioactive Compounds *17*
 - 2.4 Four-Membered Rings: Synthesis, Applications, and New Design Principles *19*
 - 2.5 Further Examples *26*
 - 2.6 Conclusions *28*
References *29*

- 3 Recent Advances in the Asymmetric Synthesis of Spiro Compounds Through Cycloadditions** *35*
Alberto Vega-Peñaloza, Suva Paria, Luca Dell'Amico, and Xavier Companyó
 - 3.1 Introduction *35*
 - 3.2 Organometallic Methodologies *36*
 - 3.2.1 Organometallic [3+2] Cycloaddition Strategies to Construct Spiro Compounds *36*
 - 3.2.2 Organometallic [4+2] Cycloaddition Strategies to Construct Spiro Compounds *42*

- 3.2.3 Organometallic Miscellaneous Strategies to Construct Spiro Compounds 44
- 3.3 Organocatalytic Methodologies 48
 - 3.3.1 Organocatalytic [3+2] Cycloaddition Strategies to Construct Spiro Compounds 48
 - 3.3.2 Organocatalytic [4+2] Cycloaddition Strategies to Construct Spiro Compounds 52
 - 3.3.3 Organocatalytic [4+3] and [2+2] Cycloaddition and Switchable Strategies to Construct Spirocompounds 55
 - 3.3.4 Organocatalytic Miscellaneous Strategies to Construct Spiro Compounds 60
 - References 62
- 4 Design and Synthesis of Spirocycles via Olefin Metathesis 65**
Sambasivarao Kotha, Vikas R. Aswar and Yellaiah Tangella
 - 4.1 Introduction 65
 - 4.2 Formation of Aza-spirocycles 84
 - 4.3 Formation of Oxa-spirocycles 87
 - 4.4 Miscellaneous Examples 97
 - References 98
- 5 Spirooxindoles: Synthesis via Organocatalytic Processes 103**
Peng-Wei Xu, Xiao-Yuan Cui, Jin-Sheng Yu, and Jian Zhou
 - 5.1 Introduction 103
 - 5.2 Enamine and Iminium Catalysis 105
 - 5.3 Chiral Nucleophilic Catalysis with Tertiary Phosphines or Amines 114
 - 5.4 Chiral *N*-Heterocyclic Carbene Catalysis 120
 - 5.5 Chiral Tertiary Amine-H-Bond Donor Bifunctional Catalysis 127
 - 5.6 Chiral Hydrogen-Bonding Catalysis 142
 - 5.7 Chiral Phosphoric Acid Catalysis 144
 - 5.8 Chiral Phase-Transfer Catalysis 149
 - 5.9 Chiral Organoiodine Catalysis 151
 - 5.10 Conclusion 153
 - References 153
- 6 Spirooxindole Synthesis by Organometallic Processes 161**
Albert Moyano
 - 6.1 Introduction 161
 - 6.2 Direct Construction of the Spirooxindole Unit by Cyclization Methodologies 161
 - 6.2.1 Intramolecular Heck Reaction and Related Cyclizations 161
 - 6.2.2 Alkylation–Cyclization of 3-Substituted Oxindoles 167
 - 6.2.3 Cyclization of 3-Substituted Indoles 170

6.3	Two-component Annulation/Cycloaddition Methodologies	171
6.3.1	Cyclopropyl Spirooxindoles by [2+1] Cycloaddition Reactions	171
6.3.2	[2+2] Cycloaddition Reactions	173
6.3.3	[3+2] Annulation/Cycloaddition Reactions	175
6.3.4	[3+3] Cycloaddition Reactions	188
6.3.5	[4+1] Cycloaddition Reactions	189
6.3.6	[4+2] Cycloaddition/Annulation Reactions	190
6.3.7	[5+2] Cycloaddition Reactions	195
6.4	Miscellaneous Methods	195
6.4.1	Darzens Reaction of Isatins	195
6.4.2	Cyclization of 3,3-Disubstituted Oxindoles	198
6.4.3	Three-component Reactions	198
6.5	Conclusions	200
	Acknowledgements	200
	References	200
7	Enantioselective Synthesis of Spiro Heterocycles	205
	<i>Michal Urban and Jan Veselý</i>	
7.1	Introduction	205
7.2	Enantioselective Synthesis of Spiro Heterocycle with One Nitrogen Atom	206
7.2.1	Enantioselective Formation of Spiropyrolidines	206
7.2.1.1	Organometallic Approaches	206
7.2.1.2	Organocatalytic Approaches	208
7.2.1.3	Cooperative-catalytic Approaches	209
7.2.2	Enantioselective Formation of Spirocycles Containing Indoline and Indolenine Ring	210
7.2.2.1	Organometallic Approaches	210
7.2.2.2	Organocatalytic Approaches	211
7.2.3	Enantioselective Formation of Spiropiperidines	214
7.2.3.1	Organometallic Approaches	214
7.2.3.2	Organocatalytic Approaches	216
7.3	Enantioselective Formation of Spirocycles Containing Heterocycle with One Oxygen Atom	218
7.3.1	Enantioselective Formation of Spirocycles Containing Dihydrofuranone and Tetrahydrofuran Ring	218
7.3.1.1	Organometallic Approaches	218
7.3.1.2	Organocatalytic Approaches	221
7.3.2	Enantioselective Formation of Spirocycles Containing Benzofuranone and Benzodihydrofuran Ring	224
7.3.2.1	Organometallic Approaches	224
7.3.2.2	Organocatalytic Approaches	227

7.3.2.3	Cooperative-catalytic Approaches	233
7.3.3	Enantioselective Formation of Spirocycles Containing Dihydrocoumarin, Dihydro- and Tetrahydropyran Ring	234
7.3.3.1	Organometallic Approaches	234
7.3.3.2	Organocatalytic Approaches	236
7.4	Enantioselective Formation of Sulfur-containing Spirocycles	240
7.5	Enantioselective Formation of Spirocycles Containing Heterocycle with More Than One Heteroatom	244
7.5.1	Enantioselective Formation of Spirocycles Containing Pyrazolone Ring	244
7.5.1.1	Organometallic Approaches	244
7.5.1.2	Organocatalytic Approaches	246
7.5.1.3	Cooperative-catalytic Approaches	255
7.5.2	Chapter 7.5.2 – Enantioselective Formation of Spirocycles Containing Barbituric Acid and Hydantoin	256
7.5.3	Chapter 7.5.3 – Enantioselective Formation of Spirocycles Containing Azlactones	259
7.5.3.1	Organometallic Approaches	259
7.5.3.2	Organocatalytic Approaches	259
7.5.3.3	Cooperative-catalytic Approaches	259
7.5.4	Chapter 7.5.4 – Enantioselective Formation of Spirocycles Containing Rhodanines and Sultams	262
7.5.4.1	Organometallic Approaches	262
7.5.4.2	Organocatalytic Approaches	264
7.5.5	Chapter 7.5.5 – Enantioselective Formation of Spiroketal (Spiroacetals)	266
7.5.5.1	Organometallic Approaches	267
7.5.5.2	Organocatalytic Approaches	268
7.5.5.3	Cooperative-catalytic Approaches	269
7.6	Enantioselective Formation of Other Spiro Heterocyclic Systems	270
7.6.1	Organometallic Approaches	270
7.6.1.1	Organocatalytic Approaches	272
7.7	Enantioselective Formation of Bispriocycles	273
7.8	Conclusion	274
	Acknowledgements	275
	References	275
8	Enantioselective Synthesis of all Carbon Spiro Compounds	283
	<i>Ramon Rios</i>	
8.1	Enantioselective Synthesis of All-Carbon Spiro Compounds Based on Alkylation Methods	285
8.2	Enantioselective Synthesis of All-Carbon Spirocycles by Metal-catalyzed Methods	286

- 8.3 Enantioselective Synthesis of All-Carbon Spirocycles by Cycloaddition Strategies 294
- 8.4 Enantioselective Synthesis of All-Carbon Spirocycles by Radical Strategies 300
- 8.5 Enantioselective Synthesis of All-Carbon Spirocycles by Cascade Reactions 301
- 8.6 Enantioselective Synthesis of All-Carbon Spirocycles by Rearrangement Strategies 307
- 8.7 Conclusions 310
- References 310

9 Transition-Metal-Catalyzed Dearomative Spiroannulation Reactions 313

Lu Bai, Jingjing Liu and Xinjun Luan

- 9.1 Introduction: Discovery of Aromatic Compounds 313
- 9.2 Development of Dearomatization Reactions 313
- 9.3 Development of Dearomative Spiroannulation Reactions 314
- 9.4 Dearomative Spiroannulations of Phenols 314
 - 9.4.1 Dearomative Spiroannulation Without Oxidants 315
 - 9.4.1.1 Dearomative Alkylation of Phenols 315
 - 9.4.1.2 Dearomative Arylation of Phenols 319
 - 9.4.2 C–H Bond Activation/Dearomative Spiroannulation Reactions 325
- 9.5 Dearomative Spiroannulation of Indoles 332
 - 9.5.1 Intramolecular Dearomative Allylic Alkylation 332
 - 9.5.2 Intramolecular Dearomative Arylation 334
 - 9.5.3 Intermolecular Dearomative Spiroannulation of Indoles 338
- 9.6 Dearomative Spiroannulation of Aromatic Heterocyclic Compounds 342
 - 9.6.1 Dearomative Spiroannulation of Pyrroles 342
 - 9.6.2 Dearomative Spiroannulation of Furans 344
 - 9.6.3 Dearomative Spiroannulation of Thiophenes 346
- 9.7 Dearomative of Other Aromatic Compounds 349
- 9.8 Conclusion 352
- References 352

10 Carbocyclic Spiro Compounds Occupying Higher Dimensions: Benzoannelated [5.5.5]Fenestranes and Beyond 357

Hak-Fun Chow and Dietmar Kuck

- 10.1 Introduction 357
- 10.2 Selected Synthesis Strategies 362
 - 10.2.1 The Access to Benzoannelated Fenestranes 365
 - 10.2.2 Derivatives of [5.5.5.6]-Fenestranones and Fenestrindane 371

10.2.3	Fenestrindanes as a Core Embedded in a Closed π -Electron Periphery	378
10.2.4	Three Spiranes Merged in a Centropolycyclic Framework: Centrohexasindane and Its Derivatives	384
10.3	Conclusions	392
	Acknowledgements	394
	References	394
11	The Synthesis of Natural Products Containing Spirocycles	401
	<i>Ramon Rios</i>	
11.1	Porco's Synthesis of (+)-Calafianin	401
11.2	Hayashi's Total Synthesis of Pseurotin A	405
11.3	Trost's Synthesis of (-)-Ushikulide A	408
11.4	Castle's and Herzon's Syntheses of (-)Acutumine	412
11.4.1	Castle's Synthesis of (-)-acutamine	413
11.4.2	Herzon's Synthesis of (-)-Acutumine	417
11.5	Overman's and Carreira's Synthesis of Spirotryprostatin B	421
11.5.1	Overman's Synthesis of Spirotryprostatin B	421
11.5.2	Carreira's Synthesis of (-)-Spirotryprostatin B	423
11.6	Conclusion	427
	References	427
	Index	429

List of Contributors

Vikas R. Aswar

Department of Chemistry, Indian Institute of Technology Bombay, Mumbai, India

Lu Bai

Key Laboratory of Synthetic and Natural Functional Molecule of the Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an, China

Matthias Baud

School of Chemistry and Institute for Life Sciences, University of Southampton, Southampton, UK

Hak-Fun Chow

Department of Chemistry, Institute of Molecular Functional Materials and The Center of Novel Functional Molecules, The Chinese University of Hong Kong, Shatin, Hong Kong

Xavier Companyó

Department of Chemical Sciences, University of Padova, Padova, PD, Italy

Xiao-Yuan Cui

School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

Luca Dell'Amico

Department of Chemical Sciences, University of Padova, Padova, PD, Italy

Sambasivarao Kotha

Department of Chemistry, Indian Institute of Technology Bombay, Mumbai, India

Dietmar Kuck

Department of Chemistry and Center for Molecular Materials (CM2), Bielefeld University, Bielefeld, Germany

Jingjing Liu

Key Laboratory of Synthetic and Natural Functional Molecule of the Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an, China

Xinjun Luan

Key Laboratory of Synthetic and Natural Functional Molecule of the Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an, China

Marta Meazza

School of Chemistry, University of Southampton, Southampton, UK

Albert Moyano

Secció de Química Orgànica, Departament de Química Inorgànica i Orgànica, Facultat de Química, Universitat de Barcelona, Barcelona, Catalonia, Spain

Suva Paria

Department of Chemical Sciences, University of Padova, Padova, PD, Italy

Ramon Rios

Department of Organic Chemistry, University of Southampton, Southampton, UK

Yellaiah Tangella

Department of Chemistry, Indian Institute of Technology Bombay, Mumbai, India

Alberto Vega-Peñaloza

Department of Chemical Sciences, University of Padova, Padova, PD, Italy

Jan Veselý

Department of Organic Chemistry, Faculty of Science, Charles University, Prague, Czech Republic

Michal Urban

Department of Organic Chemistry, Faculty of Science, Charles University, Prague, Czech Republic

Peng-Wei Xu

School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

Jin-Sheng Yu

School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

Jian Zhou

School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

Preface

When I was a kid, I dreamt to be an engineer and build planes, cars, etc. However, in high school, I felt in love with Organic Chemistry. I changed my dreams of building things for how to assemble C, H, N, and other atoms to form molecules. I was always astonished of the inherent difficulty of **organic** structures, not only for their diversity and ordered assembly but also for their 3D shape. With time, I enjoyed learning Organic Chemistry: starting from my bachelor in organic chemistry, followed by a PhD in organometallic chemistry, and several postdocs in organometallic chemistry and organocatalysis. Later on, as academic, I have always tried to develop new reactions that can allow to obtain difficult structures in an enantiopure form. However, one of the greatest challenges that I faced has been the synthesis of spiro compounds. My own way to be interested in the synthesis of spiro compounds first started in the synthesis of quaternary carbons in an enantiopure fashion. Precisely, while studying how to synthesize quaternary carbons, I developed an interest in spiro compounds, how difficult it will be to join two cycles by a single atom, and do it enantioselectively. In my research group, we have been lucky enough to develop several reactions that led to spiro compounds in an enantiopure form (or almost enantiopure), but I still remember the first time that we got a spiro compound in an enantiopure form as an incredible feeling of achievement. Now, several years later, I decided to honor this type of compounds by editing a book, summarizing the achievements that Organic Chemists have been done in the last decades.

I also want to dedicate this book to Professor Dieter Enders who left us during the writing of this book. He was always a source of inspiration, since his early success with RAMP and SAMP chemistry, until the development of highly complex domino reactions, showing a commitment and brilliance to organic chemistry that inspired me in my career. I still remember his kind hospitality in The Domino cat symposium in Aachen. Professor Enders, you left a huge footprint in organic and synthetic chemistry.

Finally, I want to thank all the authors for their work and commitment in those difficult COVID times.

1

Spiro Compounds: A Brief History

Marta Meazza

School of Chemistry, University of Southampton, Southampton, UK

Polycyclic molecules containing at least two rings joined together by a single atom, mostly a carbon atom, previously named spiranes, are called spiro compounds or spirocycles, and the single central atom is referred to as the spiro atom [1]. We should mention that apart from carbon, other elements such as nitrogen, phosphorus, and arsenic may represent the spiro atom.

The term was coined by the German chemist Nobel laureate Adolf von Baeyer who created the first spirane in 1900 [2].

This peculiar structural feature is present in natural products and has long been the subject of methodological studies and synthetic efforts [3].

Several synthetic procedures for spiro compounds have been developed and will be extensively discussed in the next chapters. However, the asymmetric synthesis of spirocycles that allow the creation of stereogenic quaternary centers represent a demanding task for organic chemists. Even the concepts of spiro aromaticity and spiro antiaromaticity can be applied when spiroconjugation is possible [4].

The search for the key term “spiro” in SciFinderⁿ database, at the end of October 2019, resulted in more than 40 700 references with an exponential growth starting from the middle of the last century and an increasing attention to this subject is expected in the future (Figure 1.1).

These massive research efforts cover a wide range of fields from organic and medicinal chemistry to material sciences and engineering, to name a few.

The enormous interest in spiro compounds rely on their distinctive properties often associated with the three-dimensional stereochemical features, reflecting on their pharmacological properties that include, among others, bactericidal, fungicidal, anticancer, cytotoxic, antidepressant, antihypertensive, insecticidal, herbicidal, and plant growth regulatory effects [5]. These properties are due to the tetrahedral nature of the spiro carbon and consequent asymmetric features associated with it.




Figure 1.1 Growing interest in spiro compounds in chemical literature.




Figure 1.2 Dye sensitizer 9,9-spirofluorene.
Source: Lupo et al. [7].

In addition, many other practical utilizations include optoelectronic devices, ophthalmic lenses, and solar cells [6]. Compounds like 9,9-spirofluorene **1** (Figure 1.2) have application in dye-sensitized solar cells (DSCs) and represent the most efficient alternative to the current solar cell technologies [7].

Spirocyclic compounds find technological application as efficient charge-transfer molecules due to their intramolecular donor–acceptor structural feature amplified by spiroconjugation. The desired optical properties can be achieved by careful design of the spiro donor–acceptor characteristic as illustrated in Figure 1.3 [8]. When structural characteristics make it possible, spiro compounds can equilibrate with their non-spiro analogues exhibiting photochemical phenomena like photochemical memory.

We report here some examples of carbocyclic and heterocyclic naturally occurring compounds containing the spiro moiety (Figure 1.4). One of the simplest compounds is the pheromone of the olive fly *Dacus oleae* **5**. Phelligrudin G **6** from the fungus *Phellinus igniarius* has been long used in Traditional Chinese Medicine for the treatment of gonorrhoea [9]. The antimycotic drug griseofulvin **7**, isolated from a penicillium mold in 1939, found application in the treatment of fungal skin




Figure 1.3 Donor–acceptor spiro compounds and colors displayed by them.
Source: Wössner et al. [8].




Figure 1.4 Examples of naturally occurring compounds containing the spiro moiety.

infections since 1957. Hecogenin **8**, the aglycone part of a steroid saponin found in the plant *Agave sisalana*, is responsible for many therapeutic effects and is also used as a starting material in the synthesis of corticosteroids [10]. Horsfiline **9** is an oxindole alkaloid having analgesic effect, isolated from the plant *Horsfieldia superba* [11].

A classic example of the importance of the presence of a spiro functionality is the retention of the biological activity of perhydrohistrionicotoxin **10**, the completely reduced analogue of the potent nicotinic receptor antagonist alkaloid (–)-histrionicotoxin **11**, isolated from “dart-poison” frogs, that clearly suggests the fundamental role of the spiro piperidine moiety in determining a strong receptor binding. The massive synthetic efforts on this topic are collected in a book chapter [12] (Figure 1.5).




Figure 1.5 Spiro functionality in nicotinic receptor antagonists. *Source:* Hart [12].

As stated before, spirocycles are present in successfully developed medications and represent attractive synthetic targets included in chemical libraries for diversity-oriented synthesis within drug discovery projects. In this context, the spiro moiety has been and can be employed both as core structure and as an activity modulator, appended to decorate the peripheral part of the molecule [13].

The major advantage of spirocycles in biological applications as core structure or pharmacophores originates from their 3-D nature and the associated conformational features that allow for a better ability to interact with the target protein enzyme. The tetrahedral feature of the spiro atom renders the two ring planes nearly perpendicular to each other with a limited number of potential conformations. When added in the periphery of the molecule, the spirocycle acts as a modulator of physicochemical properties such as log P and water solubility, as well as affecting the metabolic stability of the molecule. Not least, from an intellectual property perspective, the introduction of spirocycles offers the possibility of obtaining a free patent space in a me-too research approach.

Prominent examples of marketed spirocompounds, illustrating these concepts, include fluspirilene **12**, spiraprilat **13**, and cevimeline **14**, while experimental compounds in different stages of clinical development are ETX0914 **15**, a DNA gyrase inhibitor; tofoglifozin CSG452 **16**, an inhibitor of hSGLT2 for the treatment of Type 2 diabetes; AZD1979 **17**, an antagonist of melanin-concentrating hormone receptor; and rolapitant **18**, a neurokinine 1 receptor antagonist [13, 14] (Figure 1.6).

We wish once more to draw the attention of the readers on the potential usefulness and uniqueness of the spiro motif in the interaction with a specific biological target spanning from drugs to agrochemicals.

The enzyme Acetyl-coenzyme A carboxylases (ACCs) have crucial roles in fatty acid metabolism in most living organisms, among which include humans, insects, and plants. The experimental ACC inhibitor compounds for the treatment of human metabolic disease contain a spirocyclic moiety as in Takeda compound **19** [15] and in Pfizer PF-05221304 **20**. The last one is currently in phase II clinical trials for the treatment of Non-Alcoholic Steatohepatitis (NASH) [16] (Figure 1.7).




Figure 1.6 Examples of marketed spiro compound drugs. *Sources:* Based on Zheng and Tice [13]; Zheng et al. [14].




Figure 1.7 ACC inhibitors of pharmaceutical interest. *Sources:* Based on Bourbeau and Bartberger [16a]; Esler and Bence [16b].

The commercial insecticide/acaricide products spirotetramat **21**, spiromesifen **22**, and spiroadiclofen **23** from Bayer CS and spiropidion **24** from Syngenta, acting as insect ACC inhibitors, all have spirocyclic structures [17] (Figure 1.8).

New spirocyclic herbicide compounds with the representative formula **25** have been recently patented [18]. It is noteworthy that compounds **21** and **24**, sharing similar molecular features with **25**, do not show any phytotoxic effect (Figure 1.9).




Figure 1.8 Commercial spirocyclic insecticide/acaricide products. *Source:* Jeschke et al. [17].




Figure 1.9 Recently patented spiro compound of agrochemical interest.




Figure 1.10 Example of numbering of spirocyclic compounds.

As presented in this chapter, spirocyclic scaffolds find application in a large number of sectors for their own peculiar architecture characteristics, displaying valuable application properties, or simply because of the introduction of structural novelty that guarantee patentability and intellectual property rights.

1.1 Notes on IUPAC Rules for Spiro Compounds

Naming spirocycles could be quite complex. The accepted rules are collected in the IUPAC blue book [1, 19].

Simplifying with two examples, the structure **26** is numbered starting from the smallest cycle (Figure 1.10). The name comes from the prefix spiro followed by square brackets containing the number of atoms of the two cycles starting from the smallest and excluding the spirocenter. In this case, the functional group is an alkane so that the name became spiro[4,5]decane.




Figure 1.11 Example of naming chiral spiro compounds.

When the compound is chiral because it contains a chiral center, the CIP rules are followed. In the case in which the substituents on the spirocenter are the same, but the structures display an axial chirality as in Figure 1.11, we assign arbitrarily the priority to one of the cycles and then, within each cycle the order follows the CIP rules: $a > a' > b > b'$.

References

- 1 Moss, G. (1999). *Pure Appl. Chem.* 71: 531–558.
- 2 Baeyer, A.V. (1900). *Ber. Dtsch. Chem. Ges.* 33: 3771–3775.
- 3 (a) Singh, G.S. and Desta, Z.Y. (2012). *Chem. Rev.* 112: 6104–6155. (b) Smith, L.K. and Baxendale, I.R. (2015). *Org. Biomol. Chem.* 13: 9907–9933.
- 4 Fleming, I. (2010). *Molecular Orbitals and Organic Chemical Reactions*, Reference Edition. Chichester, UK: Wiley & Sons, Ltd.
- 5 Molvi, K.I., Haque, N., Awen, B.Z.S., and Zameeruddin, M. (2014). *World J. Pharm. Sci.* 3: 536–563.
- 6 Saragi, T.P.I., Spehr, T., Siebert, A. et al. (2007). *Chem. Rev.* 107: 1011–1065.
- 7 Lupo, D., Salbeck, J., Schenk, H. et al. (1998). Spiro compounds and their use as electroluminescence materials. Patent: US5840217, 24 November 1998.
- 8 Wössner, J.S., Grenz, D.C., Kratzert, D., and Esser, B. (2019). *Org. Chem. Front.* 6: 3649–3656.
- 9 Xu, J.-P. (2017). *Cancer Inhibitors from Chinese Natural Medicines*. Boca Raton, FL: CRC Press.
- 10 Cruz, M.S., Barroso, S.C., Navoni, J.A. et al. (2016). *Toxicol. Rep.* 3: 539–543.
- 11 Jossang, A., Jossang, P., Hadi, H.A. et al. (1991). *J. Org. Chem.* 56: 6527–6530.
- 12 Hart, D.J. (2011). *Organic Synthesis via Examination of Selected Natural Products*. Singapore: World Scientific Publishing Co Pte Ltd.
- 13 Zheng, Y. and Tice, C.M. (2016). *Expert Opin. Drug Discovery* 11: 831–834.
- 14 Zheng, Y., Tice, C.M., and Singh, S.B. (2014). *Bioorg. Med. Chem. Lett.* 24: 3673–3682.
- 15 Kamata, M., Yamashit, T., Kina, A. et al. (2012). *Bioorg. Med. Chem. Lett.* 22: 4769–4772.

- 16** (a) Bourbeau, M.P. and Bartberger, M.D. (2015). *J. Med. Chem.* 58: 525–536. (b) Esler, W.P. and Bence, K.K. (2019). *Cell. Mol. Gastroenterol. Hepatol.* 8: 247–267.
- 17** Jeschke, P., Witschel, M., Krämer, W., and Schirmer, U. (eds.) (2019). *Modern Crop Protection Compounds*, 3e. Weinheim, Germany: Wiley-VCH Verlag GmbH.
- 18** Angermann, A., Bojack, G., Buscato Arsequell, E., et al. (2019). Specifically substituted 2-alkyl-6-alkoxyphenyl-3-pyrrolin-2-ones and their use as herbicides. Patent: WO2019219588, 13 May 2019.
- 19** Favre, H.A. and Powell, W.H. (2013). *Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names*. RSC.

2

Selected Applications of Spirocycles in Medicinal Chemistry






Matthias Baud


School of Chemistry and Institute for Life Sciences, University of Southampton, Southampton, UK

2.1 Introduction

Spiro compounds contain two rings, connected by a single sp^3 hybridized quaternary center, the “spiroatom” [1]. The latter is often a carbon, although a number of quaternary *N*-spiro ammoniums have also been reported. Trospium chloride (**1**) (Table 2.1) is a good example, and its spiro ammonium motif can be readily prepared by double *N*-alkylation of endo-nortropine [3]. Spirocyclic systems are found in a wide range of natural products [4], including spiro-ketals [5, 6], lactones [7], lactams [8, 9], and oxindoles [10–12]. An early and illustrative example of spirocyclic natural product which has attracted the attention of medicinal chemists is the antibiotic platensimycin (**2**). It is a metabolite from *Streptomyces platensis* which represents a structurally unusual example of bioactive molecule containing a carbaspicyclic scaffold. Its antibiotic activity was reported by Merck in 2006, as part of a screening campaign to identify inhibitors of beta-ketoacyl synthases I/II (FabF/B) enzymes [13]. Inhibition of FAB enzymes by platensimycin leads to impaired biosynthesis of key fatty acids required bacterial cell membrane integrity [14]. Platensimycin displays activity against a range of Gram-positive bacteria, including strains showing resistance to other potent antibiotics such as methicillin, vancomycin, linezolid, or macrolide. Structural studies on an *Escherichia coli* FabF(C163Q) in complex with platensimycin highlighted important interactions underlying complex formation. The shape complementarity and conformational restriction provided by the spiro motif are important contributors to the potency of platensimycin, allowing polar interactions and hydrophobic contacts at the binding site entrance (Figure 2.1) [13]. The first total synthesis of racemic platensimycin was reported by Nicolaou on the same year (Scheme 2.1) [15], involving a key ruthenium-catalyzed enyne cycloisomerization [16]. Since then, stereoselective syntheses of platensimycin spirocyclic core based on rhodium-catalyzed asymmetric cycloisomerization and hypervalent iodine-mediated de-aromatizing cyclization [17], decarboxylative allylation [18], and intramolecular Diels–Alder [19] have been reported.


Table 2.1 Selected examples of FDA-approved drugs containing spirocyclic motifs.

Structure	ID	Name (Trade name)	Indication
	1	Trospium chloride (Flotros)	Overactive bladder
	3	Spironolactone (Aldactone)	Heart failure, edema, hypertension
	4	Cevimeline (Evoxac)	Dry mouth (Sjögren's Syndrome)
	5	Griseofulvin (Crivicin)	Antifungal antibiotic for ringworm infections
	6	Guanadrel (Hylorel)	Hypertension



7 Amcinonide
(Cyclocort)


Inflammatory and pruritic manifestations



8


Ivermectin
(AscapiI)

Anti-parasitic



9 Fenspiride
(Eurespal)

Antitussive







10 Rifabutin (Ansati-pin)

Antibiotic, tuberculosis

(Continued)


Table 2.1 (Continued)

Structure	ID	Name (Trade name)	Indication
	11	Homo-harringtonine (Ceflatonin)	Chronic myeloid leukemia
	12	Irbesartan (Avapro)	Hypertension
	13	Fluspirilene (Imap)	Schizophrenia



14 Spirapril
(Renormax)

Hypertension



15 Buspirone
(Buspar)

Anxiety disorders

Source: Adapted from Knox et al. [2].





Figure 2.1 X-ray crystal structure (pdb 2gfx¹²) of Platensimycin (**2**, sticks representation) bound to the active site of FabF (surface representation) highlights hydrophobic contacts and hydrogen bonds in the complex.



Scheme 2.1 Key enyne cycloisomerization step in Nicolaou's total synthesis of platensimycin. *Source:* Adapted from Nicolaou et al. [15].

In contrast, a comparatively small number of spirocycle containing drugs have been investigated in the last decades, and spirocyclic molecules are still under-represented in marketed drugs [2]. Selected examples of spirocycle containing drugs are shown in Table 2.1, including spironolactone **3** which has been known for over 50 years [20]. It seems fair to state that historically drug design strategies in medicinal chemistry have been heavily inspired (or biased?) by the advances in synthetic chemical methods toward new molecular scaffolds. This raises the question of chemical diversity and unconscious bias toward traditional/ubiquitous building